Yang-xin Fu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1649067/publications.pdf

Version: 2024-02-01

325 papers	38,957 citations	2093 100 h-index	3312 184 g-index
342 all docs	342 docs citations	342 times ranked	42952 citing authors

#	Article	IF	Citations
1	Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology, 2013, 14, 1014-1022.	7.0	3,109
2	Irradiation and antiâ€“PD-L1 treatment synergistically promote antitumor immunity in mice. Journal of Clinical Investigation, 2014, 124, 687-695.	3.9	1,627
3	STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity, 2014, 41, 843-852.	6.6	1,468
4	Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood, 2009, 114, 589-595.	0.6	1,146
5	Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology, 2017, 14, 365-379.	12.5	760
6	The Aryl Hydrocarbon Receptor Regulates Gut Immunity through Modulation of Innate Lymphoid Cells. Immunity, 2012, 36, 92-104.	6.6	694
7	The Efficacy of Radiotherapy Relies upon Induction of Type I Interferonâ€“Dependent Innate and Adaptive Immunity. Cancer Research, 2011, 71, 2488-2496.	0.4	692
8	A STING-activating nanovaccine for cancer immunotherapy. Nature Nanotechnology, 2017, 12, 648-654.	15.6	649
9	Commensal bacteria protect against food allergen sensitization. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13145-13150.	3.3	632
10	DEVELOPMENT AND MATURATION OF SECONDARY LYMPHOID TISSUES. Annual Review of Immunology, 1999, 17, 399-433.	9.5	613
11	CD47 blockade triggers T cellâ€“mediated destruction of immunogenic tumors. Nature Medicine, 2015, 21, 1209-1215.	15.2	605
12	Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature Reviews Cancer, 2019, 19, 568-586.	12.8	557
13	The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity. Cancer Cell, 2010, 18, 160-170.	7.7	474
14	Low-dose X-ray radiotherapyâ€“radiodynamic therapy via nanoscale metalâ€“organic frameworks enhances checkpoint blockade immunotherapy. Nature Biomedical Engineering, 2018, 2, 600-610.	11.6	438
15	Circulating and Liver Resident CD4+CD25+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B. Journal of Immunology, 2006, 177, 739-747.	0.4	399
16	Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. Journal of Experimental Medicine, 2005, 201, 779-791.	4.2	395
17	PD-L1 on host cells is essential for PD-L1 blockadeâ€“mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 580-588.	3.9	388
18	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell, 2016, 29, 285-296.	7.7	349

#	Article	IF	Citations
19	Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. Journal of Experimental Medicine, 2007, 204, 49-55.	4.2	348
20	Group 3 Innate Lymphoid Cells Inhibit T-Cell-Mediated Intestinal Inflammation through Aryl Hydrocarbon Receptor Signaling and Regulation of Microflora. Immunity, 2013, 39, 386-399.	6.6	343
21	CD95 promotes tumour growth. Nature, 2010, 465, 492-496.	13.7	339
22	Adaptive immune cells temper initial innate responses. Nature Medicine, 2007, 13, 1248-1252.	15.2	338
23	Priming of naive T cells inside tumors leads to eradication of established tumors. Nature Immunology, 2004, 5, 141-149.	7.0	331
24	Lymphotoxin Î² receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoEâ^'/â^' mice. Journal of Experimental Medicine, 2009, 206, 233-248.	4.2	331
25	Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nature Communications, 2017, 8, 1736.	5.8	304
26	Recognition of Host Immune Activation by Pseudomonas aeruginosa. Science, 2005, 309, 774-777.	6.0	301
27	TNFR2 Activates MLCK-Dependent Tight Junction Dysregulation to Cause Apoptosis-Mediated Barrier Loss and Experimental Colitis. Gastroenterology, 2013, 145, 407-415.	0.6	300
28	Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nature Medicine, 2000, 6, 283-289.	15.2	293
29	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nature Communications, 2020, 11, 4835.	5.8	290
30	Type I interferon response and innate immune sensing of cancer. Trends in Immunology, 2013, 34, 67-73.	2.9	277
31	B Lymphocytes Induce the Formation of Follicular Dendritic Cell Clusters in a Lymphotoxin Î±â€“dependent Fashion. Journal of Experimental Medicine, 1998, 187, 1009-1018.	4.2	272
32	Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ TÂcell immunity. Cell Metabolism, 2021, 33, 988-1000.e7.	7.2	264
33	Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies. Seminars in Oncology, 2010, 37, 508-516.	0.8	256
34	Tumor-infiltrating T lymphocytes: friends or foes?. Laboratory Investigation, 2006, 86, 231-245.	1.7	246
35	Immunotherapy and tumor microenvironment. Cancer Letters, 2016, 370, 85-90.	3.2	242
36	Targeting the Tumor Microenvironment with Interferon-Î² Bridges Innate and Adaptive Immune Responses. Cancer Cell, 2014, 25, 37-48.	7.7	236

#	Article	IF	Citations
37	Induction of Innate Lymphoid Cell-Derived Interleukin-22 by the Transcription Factor STAT3 Mediates Protection against Intestinal Infection. Immunity, 2014, 40, 25-39.	6.6	221
38	Increasing Tumor Antigen Expression Overcomes â€œIgnoranceâ€•to Solid Tumors via Crosspresentation by Bone Marrow-Derived Stromal Cells. Immunity, 2002, 17, 737-747.	6.6	216
39	Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. Journal of Experimental Medicine, 2010, 207, 1791-1804.	4.2	211
40	Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein Î± Signaling. Immunity, 2017, 47, 363-373.e5.	6.6	209
41	The regulation of T cell homeostasis and autoimmunity by T cellâ€“derived LIGHT. Journal of Clinical Investigation, 2001, 108, 1771-1780.	3.9	204
42	Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. Nature Communications, 2020, 11, 4909.	5.8	199
43	Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control. Journal of Experimental Medicine, 2003, 198, 1023-1034.	4.2	196
44	Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature, 2003, 425, 957-962.	13.7	195
45	OX40 signaling favors the induction of TH9 cells and airway inflammation. Nature Immunology, 2012, 13, 981-990.	7.0	195
46	Hepatitis B Virus Infection and Immunopathogenesis in a Humanized Mouse Model: Induction of Human-Specific Liver Fibrosis and M2-Like Macrophages. PLoS Pathogens, 2014, 10, e1004032.	2.1	191
47	The role of tumor-associated macrophages in breast cancer progression. International Journal of Oncology, 2013, 43, 5-12.	1.4	188
48	Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2002, 168, 1457-1465.	0.4	184
49	Lymphotoxin pathway directs thymic Aire expression. Nature Immunology, 2003, 4, 1121-1127.	7.0	182
50	Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. Journal of Clinical Investigation, 2006, 116, 2682-2694.	3.9	181
51	Lymphotoxin Controls the IL-22 Protection Pathway in Gut Innate Lymphoid Cells during Mucosal Pathogen Challenge. Cell Host and Microbe, 2011, 10, 44-53.	5.1	180
52	Lymphotoxin-Î± (LTÎ±) Supports Development of Splenic Follicular Structure That Is Required for IgG Responses. Journal of Experimental Medicine, 1997, 185, 2111-2120.	4.2	179
53	OTUD7B controls non-canonical NF-ÎºB activation through deubiquitination of TRAF3. Nature, 2013, 494, 371-374.	13.7	179
54	IL-22ÂUpregulates Epithelial Claudin-2 to Drive Diarrhea and Enteric Pathogen Clearance. Cell Host and Microbe, 2017, 21, 671-681.e4.	5.1	178

#	Article	IF	Citations
55	LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature, 2018, 562, 605-609.	13.7	172
56	Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. Journal of Experimental Medicine, 2020, 217, .	4.2	172
57	Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine, 2002, 8, 1405-1413.	15.2	171
58	The role of herpesvirus entry mediator as a negative regulator of T cellâ€“mediated responses. Journal of Clinical Investigation, 2005, 115, 711-717.	3.9	169
59	Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. Journal of Experimental Medicine, 2010, 207, 1161-1172.	4.2	160
60	NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood, 2006, 107, 1342-1351.	0.6	158
61	LIGHT Signals Directly to Intestinal Epithelia to Cause Barrier Dysfunction via Cytoskeletal and Endocytic Mechanisms. Gastroenterology, 2007, 132, 2383-2394.	0.6	157
62	Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nature Biomedical Engineering, 2021, 5, 455-466.	11.6	157
63	Non-canonical NF-Î¹B Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. Immunity, 2018, 49, 490-503.e4.	6.6	155
64	Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation, 2014, 124, 2668-2682.	3.9	154
65	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell, 2021, 39, 96-108.e6.	7.7	153
66	Dynamic Programmed Death 1 Expression by Virus-Specific CD8 T Cells Correlates With the Outcome of Acute Hepatitis B. Gastroenterology, 2008, 134, 1938-1949.e3.	0.6	152
67	A Critical Role of the IL-1Î²â€“IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. Journal of Investigative Dermatology, 2019, 139, 146-156.	0.3	152
68	Tumor-reprogrammed resident T cells resist radiation to control tumors. Nature Communications, 2019, 10, 3959.	5.8	151
69	Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7528-7533.	3.3	150
70	Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology, 2014, 59, 1331-1342.	3.6	150
71	The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications. Science Immunology, 2016, 1, .	5.6	149
72	Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. Journal of Clinical Investigation, 2004, 113, 694-700.	3.9	146

#	Article	IF	Citations
73	B Cell Maintenance of Subcapsular Sinus Macrophages Protects against a Fatal Viral Infection Independent of Adaptive Immunity. Immunity, 2012, 36, 415-426.	6.6	145
74	Lymphotoxin Beta Receptor Signaling in Intestinal Epithelial Cells Orchestrates Innate Immune Responses against Mucosal Bacterial Infection. Immunity, 2010, 32, 403-413.	6.6	144
75	The Requirement of Membrane Lymphotoxin for the Presence of Dendritic Cells in Lymphoid Tissues. Journal of Experimental Medicine, 1999, 190, 629-638.	4.2	140
76	Signaling via LTÎ²R on the lamina propria stromal cells of the gut is required for IgA production. Nature Immunology, 2002, 3, 576-582.	7.0	140
77	Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cellâ€“Mediated Killing. Journal of Immunology, 2013, 190, 5874-5881.	0.4	140
78	Recruitment and Activation of Naive T Cells in the Islets by Lymphotoxin Î² Receptor-Dependent Tertiary Lymphoid Structure. Immunity, 2006, 25, 499-509.	6.6	139
79	Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nature Communications, 2015, 6, 7114.	5.8	139
80	Is CD47 an innate immune checkpoint for tumor evasion?. Journal of Hematology and Oncology, 2017, 10, 12.	6.9	139
81	Lymphotoxin Â Receptor-Dependent Control of Lipid Homeostasis. Science, 2007, 316, 285-288.	6.0	136
82	Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nature Nanotechnology, 2020, 15, 406-416.	15.6	134
83	Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. Immunological Reviews, 1997, 156, 137-144.	2.8	133
84	Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. Journal of Clinical Investigation, 2006, 116, 2622-2632.	3.9	133
85	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature Communications, 2019, 10, 3874.	5.8	132
86	The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nature Communications, 2019, 10, 1125.	5.8	131
87	B7DC/PDL2 Promotes Tumor Immunity by a PD-1â€“independent Mechanism. Journal of Experimental Medicine, 2003, 197, 1721-1730.	4.2	130
88	Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nature Immunology, 2012, 13, 947-953.	7.0	128
89	B and T lymphocyte attenuator regulates CD8+ T cellâ€“intrinsic homeostasis and memory cell generation. Nature Immunology, 2007, 8, 162-171.	7.0	124
90	Distinct Roles of Lymphotoxin Î± and the Type I Tumor Necrosis Factor (TNF) Receptor in the Establishment of Follicular Dendritic Cells from Nonâ€“Bone Marrowâ€“derived Cells. Journal of Experimental Medicine, 1997, 186, 1997-2004.	4.2	122

#	Article	IF	Citations
91	Requirement for membrane lymphotoxin in natural killer cell development. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 6336-6340.	3.3	122
92	The role of stroma in immune recognition and destruction of well-established solid tumors. Current Opinion in Immunology, 2006, 18, 226-231.	2.4	117
93	CD160 is essential for NK-mediated IFN-Î³ production. Journal of Experimental Medicine, 2015, 212, 415-429.	4.2	116
94	Tissue-resident CD4 ⁺ T helper cells assist the development of protective respiratory B and CD8 ⁺ T cell memory responses. Science Immunology, 2021, 6, .	5.6	116
95	NF-ÎºB2 is required for the establishment of central tolerance through an Aire-dependent pathway. Journal of Clinical Investigation, 2006, 116, 2964-2971.	3.9	116
96	Reversal of Spontaneous Autoimmune Insulitis in Nonobese Diabetic Mice by Soluble Lymphotoxin Receptor. Journal of Experimental Medicine, 2001, 193, 1327-1332.	4.2	114
97	Cytokine regulation of secondary lymphoid organ development. Current Opinion in Immunology, 1998, 10, 289-297.	2.4	113
98	Lymphotoxin signalling in immune homeostasis and the control of microorganisms. Nature Reviews Immunology, 2013, 13, 270-279.	10.6	112
99	Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses. Molecular Therapy, 2013, 21, 91-100.	3.7	111
100	A mouse model for HBV immunotolerance and immunotherapy. Cellular and Molecular Immunology, 2014, 11, 71-78.	4.8	110
101	Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype. Journal of Immunology, 2015, 194, 4997-5006.	0.4	108
102	MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. Cancer Cell, 2021, 39, 109-121.e5.	7.7	108
103	B Cells Control the Migration of a Subset of Dendritic Cells into B Cell Follicles Via CXC Chemokine Ligand 13 in a Lymphotoxin-Dependent Fashion. Journal of Immunology, 2002, 168, 5117-5123.	0.4	107
104	The regulation of T cell homeostasis and autoimmunity by T cellâ€“derived LIGHT. Journal of Clinical Investigation, 2001, 108, 1771-1780.	3.9	106
105	Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Research, 1990, 50, 227-34.	0.4	103
106	Innate Lymphoid Cells Control Early Colonization Resistance against Intestinal Pathogens through ID2-Dependent Regulation of the Microbiota. Immunity, 2015, 42, 731-743.	6.6	102
107	Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. Journal of Clinical Investigation, 2004, 113, 826-835.	3.9	99
108	Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis. Cancer Cell, 2019, 35, 901-915.e4.	7.7	98

#	Article	IF	Citations
109	Tolerogenic Properties of Lymphatic Endothelial Cells Are Controlled by the Lymph Node Microenvironment. PLoS ONE, 2014, 9, e87740.	1.1	95
110	Coordination between NF-Î²B family members p50 and p52 is essential for mediating LTÎ²R signals in the development and organization of secondary lymphoid tissues. Blood, 2006, 107, 1048-1055.	0.6	93
111	Independent signals regulate development of primary and secondary follicle structure in spleen and mesenteric lymph node. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 5739-5743.	3.3	92
112	Impaired Affinity Maturation inCr2â^'/â^' Mice Is Rescued by Adjuvants Without Improvement in Germinal Center Development. Journal of Immunology, 2000, 165, 3119-3127.	0.4	91
113	Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. Cell Reports, 2018, 24, 2101-2111.	2.9	90
114	Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. Clinical Cancer Research, 2020, 26, 1359-1371.	3.2	90
115	GITR subverts Foxp3+ Tregs to boost Th9 immunity through regulation of histone acetylation. Nature Communications, 2015, 6, 8266.	5.8	89
116	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Reports, 2021, 36, 109422.	2.9	89
117	Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. Journal of Clinical Investigation, 2003, 112, 1495-1505.	3.9	86
118	Gadd45Î² promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. Journal of Clinical Investigation, 2008, 118, 1911-1923.	3.9	85
119	Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Science Translational Medicine, 2016, 8, 333ra47.	5.8	83
120	The Critical Role of LIGHT in Promoting Intestinal Inflammation and Crohnâ€™s Disease. Journal of Immunology, 2005, 174, 8173-8182.	0.4	82
121	The Inhibitory HVEM-BTLA Pathway Counter Regulates Lymphotoxin Î² Receptor Signaling to Achieve Homeostasis of Dendritic Cells. Journal of Immunology, 2008, 180, 238-248.	0.4	80
122	Therapeutic Activity of High-Dose Intratumoral IFN-Î² Requires Direct Effect on the Tumor Vasculature. Journal of Immunology, 2014, 193, 4254-4260.	0.4	79
123	Macrophage-derived IL-1Î± promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity. Cellular and Molecular Immunology, 2018, 15, 973-982.	4.8	79
124	Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nature Immunology, 2020, 21, 546-554.	7.0	78
125	Complementary Effects of TNF and Lymphotoxin on the Formation of Germinal Center and Follicular Dendritic Cells. Journal of Immunology, 2001, 166, 330-337.	0.4	76
126	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology, 2020, 17, 13-26.	4.8	76

#	Article	IF	Citations
127	The ETS1 transcription factor is required for the development and cytokine-induced expansion of ILC2. Journal of Experimental Medicine, 2016, 213, 687-696.	4.2	75
128	A novel method for synthetic vaccine construction based on protein assembly. Scientific Reports, 2014, 4, 7266.	1.6	73
129	eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nature Cancer, 2020, 1, 533-545.	5.7	73
130	The human BCL6 transgene promotes the development of lymphomas in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14198-14203.	3.3	72
131	Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases. Journal of Immunology, 2007, 179, 1960-1968.	0.4	72
132	The Critical Role of LIGHT, a TNF Family Member, in T Cell Development. Journal of Immunology, 2001, 167, 5099-5105.	0.4	70
133	Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma. Cancer Research, 2008, 68, 1563-1571.	0.4	70
134	Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. Cancer Cell, 2020, 38, 400-411.e6.	7.7	70
135	Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T Cells. Journal of Experimental Medicine, 2003, 197, 985-995.	4.2	69
136	The balance of immune responses: costimulation verse coinhibition. Journal of Molecular Medicine, 2005, 83, 193-202.	1.7	69
137	A Dendritic-Cell-Stromal Axis Maintains Immune Responses in Lymph Nodes. Immunity, 2015, 42, 719-730.	6.6	69
138	Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. Journal of Immunology, 2016, 196, 3079-3087.	0.4	69
139	Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. OncoImmunology, 2014, 3, e28499.	2.1	68
140	Gliomas Interact with Non-glioma Brain Cells via Extracellular Vesicles. Cell Reports, 2020, 30, 2489-2500.e5.	2.9	68
141	Blockade of LIGHT/LTÎ² and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 549-557.	3.9	68
142	The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. European Journal of Immunology, 2002, 32, 1969.	1.6	67
143	From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. Clinical Cancer Research, 2016, 22, 20-25.	3.2	67
144	Stimulating Lymphotoxin Î² Receptor on the Dendritic Cells Is Critical for Their Homeostasis and Expansion. Journal of Immunology, 2005, 175, 6997-7002.	0.4	66

#	Article	IF	Citations
145	T Cell-Derived Lymphotoxin Regulates Liver Regeneration. Gastroenterology, 2009, 136, 694-704.e4.	0.6	66
146	Radiation-inducible Immunotherapy for Cancer: Senescent Tumor Cells as a Cancer Vaccine. Molecular Therapy, 2012, 20, 1046-1055.	3.7	66
147	Tumor necrosis factor family members and inflammatory bowel disease. Immunological Reviews, 2005, 204, 144-155.	2.8	65
148	Contribution of the Lymphotoxin Î² Receptor to Liver Regeneration. Journal of Immunology, 2005, 175, 1295-1300.	0.4	65
149	Signal Via Lymphotoxin-Î²R on Bone Marrow Stromal Cells Is Required for an Early Checkpoint of NK Cell Development. Journal of Immunology, 2001, 166, 1684-1689.	0.4	64
150	Developmental pathway of CD4⁺CD8^{â^'}medullary thymocytes during mouse ontogeny and its defect inAire^{â^'/â^'}mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18175-18180.	3.3	64
151	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nature Communications, 2021, 12, 2768.	5.8	62
152	Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget, 2016, 7, 43039-43051.	0.8	62
153	Lymphotoxin-Î±-Dependent Spleen Microenvironment Supports the Generation of Memory B Cells and Is Required for Their Subsequent Antigen-Induced Activation. Journal of Immunology, 2000, 164, 2508-2514.	0.4	61
154	Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer. Cancer Immunology Research, 2013, 1, 123-133.	1.6	61
155	Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy. Journal of Controlled Release, 2019, 300, 154-160.	4.8	61
156	Targeting IFNÎ± to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nature Communications, 2018, 9, 4586.	5.8	60
157	Splenic Macrophages From Tumor-Bearing Mice Co-Expressing MAC-1 and MAC-2 Antigens Exert Immunoregulatory Functions Via Two Distinct Mechanisms. Journal of Leukocyte Biology, 1991, 49, 126-138.	1.5	59
158	Tbet and IL-36Î³ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. OncoImmunology, 2017, 6, e1322238.	2.1	59
159	De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. Science Translational Medicine, 2020, 12, .	5.8	59
160	Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine, 2002, 8, 1405-1413.	15.2	58
161	Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein. Journal of Experimental Medicine, 2000, 191, 1945-1956.	4.2	57
162	Lymphotoxin Î² Receptor Is Required for the Migration and Selection of Autoreactive T Cells in Thymic Medulla. Journal of Immunology, 2007, 179, 8069-8075.	0.4	57

#	Article	IF	Citations
163	The confluence of radiotherapy and immunotherapy. Frontiers in Oncology, 2012, 2, 143.	1.3	56
164	Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load. Journal of Clinical Investigation, 2018, 128, 4179-4191.	3.9	56
165	Lymphotoxin-Î² Receptor-Dependent Genes in Lymph Node and Follicular Dendritic Cell Transcriptomes. Journal of Immunology, 2005, 174, 5526-5536.	0.4	55
166	NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nature Communications, 2019, 10, 3251.	5.8	55
167	Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. Journal of Immunology, 1991, 147, 2816-23.	0.4	55
168	Essential Role of Lymph Nodes in Contact Hypersensitivity Revealed in Lymphotoxin-Î±â€“Deficient Mice. Journal of Experimental Medicine, 2001, 193, 1227-1238.	4.2	54
169	B and T Lymphocyte Attenuator Tempers Early Infection Immunity. Journal of Immunology, 2009, 183, 1946-1951.	0.4	54
170	Effective Anti-Neuâ€“Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells. Clinical Cancer Research, 2013, 19, 1476-1486.	3.2	54
171	Secondary Lymphoid Organs Are Important But Not Absolutely Required for Allograft Responses. American Journal of Transplantation, 2003, 3, 259-266.	2.6	53
172	Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine and Growth Factor Reviews, 2008, 19, 285-294.	3.2	52
173	Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cellular and Molecular Immunology, 2017, 14, 809-818.	4.8	52
174	The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. Journal of Immunology, 1991, 146, 783-9.	0.4	51
175	Antigen persistence is required for somatic mutation and affinity maturation of immunoglobulin. European Journal of Immunology, 2000, 30, 2226-2234.	1.6	49
176	Lymphotoxin Pathway-Directed, Autoimmune Regulator-Independent Central Tolerance to Arthritogenic Collagen. Journal of Immunology, 2006, 177, 290-297.	0.4	49
177	A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Science Translational Medicine, 2021, 13, .	5.8	49
178	Suppression of local type I interferon by gut microbiotaâ€“derived butyrate impairs antitumor effects of ionizing radiation. Journal of Experimental Medicine, 2021, 218, .	4.2	49
179	Cutting Edge: Membrane Lymphotoxin Regulates CD8+ T Cell-Mediated Intestinal Allograft Rejection. Journal of Immunology, 2001, 167, 4796-4800.	0.4	48
180	Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Current Opinion in Immunology, 2003, 15, 725-730.	2.4	48

#	Article	IF	Citations
181	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Research, 2021, 31, 1011-1023.	5.7	48
182	Interferon-induced mechanosensing defects impede apoptotic cell clearance in lupus. Journal of Clinical Investigation, 2015, 125, 2877-2890.	3.9	48
183	LIGHT Is Critical for IL-12 Production by Dendritic Cells, Optimal CD4+ Th1 Cell Response, and Resistance to Leishmania major. Journal of Immunology, 2007, 179, 6901-6909.	0.4	47
184	Lymphotoxin Â Receptor (LtÂR): Dual Roles in Demyelination and Remyelination and Successful Therapeutic Intervention Using LtÂR-Ig Protein. Journal of Neuroscience, 2007, 27, 7429-7437.	1.7	46
185	Cutting Edge: B and T Lymphocyte Attenuator Signaling on NKT Cells Inhibits Cytokine Release and Tissue Injury in Early Immune Responses. Journal of Immunology, 2009, 183, 32-36.	0.4	46
186	LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response. Cancer Research, 2012, 72, 2980-2989.	0.4	45
187	LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity. Cell Research, 2019, 29, 391-405.	5.7	45
188	LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. Cancer Research, 2017, 77, 1880-1891.	0.4	44
189	Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology, 2017, 66, 1067-1082.	3.6	44
190	Lymphotoxin Is Required for Maintaining Physiological Levels of Serum IgE That Minimizes Th1-mediated Airway Inflammation. Journal of Experimental Medicine, 2003, 198, 1643-1652.	4.2	43
191	Growth-factor receptor-bound protein-2 (Grb2) signaling in B cells controls lymphoid follicle organization and germinal center reaction. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7926-7931.	3.3	43
192	Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. Cell Discovery, 2017, 3, 17007.	3.1	43
193	PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. Cancer Discovery, 2016, 6, 477-478.	7.7	41
194	Adapting conventional cancer treatment for immunotherapy. Journal of Molecular Medicine, 2016, 94, 489-495.	1.7	41
195	Bap180/Baf180 is required to maintain homeostasis of intestinal innate immune response in Drosophila and mice. Nature Microbiology, 2017, 2, 17056.	5.9	41
196	Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1306-1316.	0.4	41
197	The role of core TNF/LIGHT family members in lymph node homeostasis and remodeling. Immunological Reviews, 2011, 244, 75-84.	2.8	40
198	Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice. Molecular Therapy, 2011, 19, 1727-1736.	3.7	40

#	Article	IF	Citations
199	A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice. OncoImmunology, 2016, 5, e1147641.	2.1	40
200	Targeting the myeloid checkpoint receptor SIRPÎ± potentiates innate and adaptive immune responses to promote anti-tumor activity. Journal of Hematology and Oncology, 2020, 13, 160.	6.9	40
201	Dual targeting of CTLA-4 and CD47 on T _{reg} cells promotes immunity against solid tumors. Science Translational Medicine, 2021, 13, .	5.8	39
202	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nature Communications, 2021, 12, 5866.	5.8	39
203	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. Journal of Clinical Investigation, 2022, 132, .	3.9	38
204	The Role of LIGHT in T Cell-Mediated Immunity. Immunologic Research, 2004, 30, 201-214.	1.3	37
205	Expression of LIGHT/TNFSF14 Combined with Vaccination against Human Papillomavirus Type 16 E7 Induces Significant Tumor Regression. Cancer Research, 2010, 70, 3955-3964.	0.4	36
206	A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Science Immunology, 2022, 7, eabi6899.	5.6	36
207	Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunological Reviews, 2009, 229, 232-243.	2.8	35
208	CTLA-4 Limits Anti-CD20â€“Mediated Tumor Regression. Clinical Cancer Research, 2017, 23, 193-203.	3.2	35
209	Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Science Translational Medicine, 2021, 13, .	5.8	35
210	Modulation of the Immune System by Mammary Tumor-Derived Factors. Cancer Investigation, 1991, 9, 643-653.	0.6	34
211	Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nature Communications, 2021, 12, 1281.	5.8	34
212	Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Research, 2021, 31, 1190-1198.	5.7	34
213	Antigen persistence is required for somatic mutation and affinity maturation of immunoglobulin. European Journal of Immunology, 2000, 30, 2226.	1.6	34
214	The AIM2 and NLRP3 inflammasomes trigger IL-1â€“mediated antitumor effects during radiation. Science Immunology, 2021, 6, .	5.6	33
215	Multimodality therapy of an acquired factor V inhibitor. , 1996, 51, 315-318.		32
216	Blockade of LIGHT/LTÎ² and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 549-557.	3.9	32

#	Article	IF	Citations
217	Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nature Biomedical Engineering, 2021, 5, 1261-1273.	11.6	32
218	B and T Lymphocyte Attenuator Down-regulation by HIV-1 Depends on Type I Interferon and Contributes to T-Cell Hyperactivation. Journal of Infectious Diseases, 2011, 203, 1668-1678.	1.9	30
219	Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science Immunology, 2019, 4, .	5.6	30
220	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3â€“CD8+ T cells. JCI Insight, 2020, 5, .	2.3	30
221	Inhibition of Th2-Mediated Allergic Airway Inflammatory Disease by CD137 Costimulation. Journal of Immunology, 2006, 177, 814-821.	0.4	29
222	Phospholipase CÎ³2 Mediates RANKL-stimulated Lymph Node Organogenesis and Osteoclastogenesis. Journal of Biological Chemistry, 2008, 283, 29593-29601.	1.6	29
223	CD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nature Communications, 2019, 10, 3258.	5.8	29
224	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 TÂcells. Cell Reports Medicine, 2022, 3, 100554.	3.3	29
225	Decreased macrophage-mediated cytotoxicity in mammary-tumor-bearing mice is related to alteration of nitric-oxide production and/or release. International Journal of Cancer, 1995, 60, 660-667.	2.3	28
226	Regulation of Follicular Dendritic Cell Networks by Activated T Cells: The Role of CD137 Signaling. Journal of Immunology, 2005, 175, 884-890.	0.4	28
227	LIGHT Regulates Inflamed Draining Lymph Node Hypertrophy. Journal of Immunology, 2011, 186, 7156-7163.	0.4	28
228	Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends in Molecular Medicine, 2015, 21, 463-465.	3.5	28
229	Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. , 2019, 7, 79.		28
230	Regulation of leukocyte binding to endothelial tissues by tumor-derived GM-CSF. International Journal of Cancer, 1992, 50, 585-588.	2.3	27
231	A role for lymphotoxin in the acquisition of Ly49 receptors during NK cell development. European Journal of Immunology, 2004, 34, 2699-2707.	1.6	27
232	The Role of Lymphotoxin Receptor Signaling in Diseases. Current Molecular Medicine, 2007, 7, 567-578.	0.6	27
233	Do adaptive immune cells suppress or activate innate immunity?. Trends in Immunology, 2009, 30, 8-12.	2.9	27
234	RIG-Iâ€“Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy. Cancer Research, 2020, 80, 5633-5641.	0.4	27

#	Article	IF	Citations
235	Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. Seminars in Radiation Oncology, 2020, 30, 129-138.	1.0	27
236	A single factor elicits multilineage reprogramming of astrocytes in the adult mouse striatum. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2107339119.	3.3	27
237	LTÎ²R controls thymic portal endothelial cells for haematopoietic progenitor cell homing and T-cell regeneration. Nature Communications, 2016, 7, 12369.	5.8	26
238	Next-generation cytokines for cancer immunotherapy. Antibody Therapeutics, 2021, 4, 123-133.	1.2	26
239	LIGHT (a Cellular Ligand for Herpes Virus Entry Mediator and Lymphotoxin Receptor)-Mediated Thymocyte Deletion Is Dependent on the Interaction Between TCR and MHC/Self-Peptide. Journal of Immunology, 2003, 170, 3986-3993.	0.4	25
240	A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight, 2020, 5, .	2.3	25
241	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends in Immunology, 2016, 37, 141-153.	2.9	24
242	All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Science Immunology, 2021, 6, .	5.6	24
243	Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response. Arthritis and Rheumatism, 2005, 52, 3202-3209.	6.7	22
244	Opposite Effects of Coinjection and Distant Injection of Mesenchymal Stem Cells on Breast Tumor Cell Growth. Stem Cells Translational Medicine, 2016, 5, 1216-1228.	1.6	22
245	Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nature Communications, 2020, 11, 1578.	5.8	22
246	Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. Clinical Cancer Research, 2021, 27, 3818-3824.	3.2	21
247	Membrane lymphotoxin is required for resistance to Theiler's virus infection. International Immunology, 2003, 15, 955-962.	1.8	20
248	Lymphotoxin in physiology of lymphoid tissues â€“ Implication for antiviral defense. Cytokine, 2018, 101, 39-47.	1.4	20
249	A bioactive mammalian disaccharide associated with autoimmunity activates STING-TBK1-dependent immune response. Nature Communications, 2019, 10, 2377.	5.8	20
250	Cytokines that target immune killer cells against tumors. Cellular and Molecular Immunology, 2020, 17, 722-727.	4.8	20
251	Promoting Immune Responses by LIGHT in the Face of Abundant Regulatory T Cell Inhibition. Journal of Immunology, 2010, 184, 1589-1595.	0.4	19
252	Yersinia pseudotuberculosis Exploits CD209 Receptors for Promoting Host Dissemination and Infection. Infection and Immunity, 2019, 87, .	1.0	19

#	Article	IF	Citations
253	Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nature Cancer, 2022, 3, 437-452.	5.7	19
254	Blockade of Lymphotoxin Signaling Inhibits the Clinical Expression of Murine Graft-versus-Host Skin Disease. Journal of Immunology, 2004, 172, 1630-1636.	0.4	18
255	Coordinating Development of Medullary Thymic Epithelial Cells. Immunity, 2008, 29, 386-388.	6.6	18
256	IgE regulates T helper cell differentiation through FcÎ³RIII mediated dendritic cell cytokine modulation. Cellular Immunology, 2010, 264, 54-60.	1.4	18
257	Intratumoral heterogeneity impacts the response to anti-neu antibody therapy. BMC Cancer, 2014, 14, 647.	1.1	18
258	A BTLA-Mediated Bait and Switch Strategy Permits Listeria Expansion in CD8Î±+ DCs to Promote Long-Term T Cell Responses. Cell Host and Microbe, 2014, 16, 68-80.	5.1	18
259	DNA sensing and immune responses in cancer therapy. Current Opinion in Immunology, 2017, 45, 16-20.	2.4	18
260	Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17134-17139.	3.3	17
261	Targeting tumor cells with antibodies enhances anti-tumor immunity. Biophysics Reports, 2018, 4, 243-253.	0.2	17
262	CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells. Frontiers in Immunology, 2020, 11, 2188.	2.2	16
263	Lymphotoxin Î±Î²2 (Membrane Lymphotoxin) Is Critically Important for Resistance toLeishmania majorInfection in Mice. Journal of Immunology, 2007, 179, 5358-5366.	0.4	15
264	Direct and indirect roles of the LTÎ²R pathway in central tolerance induction. Trends in Immunology, 2010, 31, 325-331.	2.9	15
265	Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice. Virology Journal, 2022, 19, 2.	1.4	15
266	A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. Journal of Clinical Medicine, 2022, 11, 4164.	1.0	15
267	Confounding factors complicate conclusions in aly model. Nature Medicine, 2001, 7, 1165-1165.	15.2	14
268	Lymphotoxin organizes contributions to host defense and metabolic illness from innate lymphoid cells. Cytokine and Growth Factor Reviews, 2014, 25, 227-233.	3.2	14
269	Innate lymphoid cells facilitate NK cell development through a lymphotoxin-mediated stromal microenvironment. Journal of Experimental Medicine, 2014, 211, 1421-1431.	4.2	14
270	Lymphoid microenvironment in the gut for immunoglobulin A and inflammation. Immunological Reviews, 2003, 195, 190-201.	2.8	13

#	Article	IF	Citations
271	Purification and Adoptive Transfer of Group 3 Gut Innate Lymphoid Cells. Methods in Molecular Biology, 2016, 1422, 189-196.	0.4	13
272	The Interaction between Lymphoid Tissue Inducer-Like Cells and T Cells in the Mesenteric Lymph Node Restrains Intestinal Humoral Immunity. Cell Reports, 2020, 32, 107936.	2.9	13
273	Enhanced local delivery with reduced systemic toxicity: Delivery, delivery, and delivery. Gene Therapy, 2006, 13, 1131-1132.	2.3	12
274	Radiation-induced tumor dormancy reflects an equilibrium between the proliferation and T lymphocyte-mediated death of malignant cells. OncoImmunology, 2013, 2, e25668.	2.1	12
275	Immune Evasion in Tumorâ€™s Own Sweet Way. Cell Metabolism, 2018, 27, 945-946.	7.2	12
276	ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth. Cancer Research, 2021, 81, 174-186.	0.4	12
277	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 6716-6725.	3.2	12
278	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer Immunology Research, 2022, 10, 829-843.	1.6	12
279	Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. Current Pathobiology Reports, 2013, 1, 37-42.	1.6	11
280	Deficiency of CD40 Reveals an Important Role for LIGHT in Anti-LeishmaniaImmunity. Journal of Immunology, 2015, 195, 194-202.	0.4	11
281	Î²-Catenin regulates tumor-derived PD-L1. Journal of Experimental Medicine, 2020, 217, .	4.2	11
282	Chemotherapy Induces Cancer-Fighting B Cells. Cell, 2020, 180, 1037-1039.	13.5	11
283	Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation. Cellular and Molecular Immunology, 2018, 15, 697-709.	4.8	11
284	Thymic atrophy induced by murine mammary adenocarcinoma in vivo. In Vivo, 1989, 3, 1-5.	0.6	11
285	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunology Research, 2017, 5, 560-570.	1.6	10
286	Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy. Oncogene, 2021, 40, 885-898.	2.6	10
287	LIGHT/TNFSR14 Can Regulate Hepatic Lipase Expression by Hepatocytes Independent of T Cells and Kupffer Cells. PLoS ONE, 2013, 8, e54719.	1.1	10
288	New immune therapy targets tumor-associated environment: from bone marrow to tumor site. Cellular and Molecular Immunology, 2012, 9, 1-2.	4.8	9

#	Article	IF	Citations
289	Cutting Edge: Lymphotoxin Signaling Is Essential for Clearance ofSalmonellafrom the Gut Lumen and Generation of Anti-SalmonellaProtective Immunity. Journal of Immunology, 2017, 198, 55-60.	0.4	9
290	Another way to not get eaten. Nature Immunology, 2018, 19, 6-7.	7.0	9
291	Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy. Methods in Molecular Biology, 2018, 1845, 275-286.	0.4	9
292	The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein and Cell, 2012, 3, 441-449.	4.8	8
293	Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication. Scientific Reports, 2015, 5, 10406.	1.6	8
294	A PI3K p110Î±-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice. OncoImmunology, 2018, 7, e1421890.	2.1	7
295	T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. Scientific Reports, 2018, 8, 17727.	1.6	7
296	T Cell-Derived Lymphotoxin Is Essential for the Anti-Herpes Simplex Virus 1 Humoral Immune Response. Journal of Virology, 2018, 92, .	1.5	7
297	Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01. Cell Discovery, 2021, 7, 114.	3.1	7
298	Co-stimulation agonists as a new immunotherapy for autoimmune diseases. Trends in Molecular Medicine, 2003, 9, 483-489.	3.5	6
299	LIGHT Induces Distinct Signals to Clear an AAV-Expressed Persistent Antigen in the Mouse Liver and to Induce Liver Inflammation. PLoS ONE, 2010, 5, e10585.	1.1	6
300	IMMUNOLOGY: Autoreactive B Cells Migrate into T Cell Territory. Science, 2002, 297, 2006-2008.	6.0	5
301	Targeting and utilizing primary tumors as live vaccines: changing strategies. Cellular and Molecular Immunology, 2012, 9, 20-26.	4.8	5
302	Linking the microbiota and metabolic disease with lymphotoxin. International Immunology, 2013, 25, 397-403.	1.8	5
303	The Inhibitory PVRL1/PVR/TIGIT Axis in Immune Therapy for Hepatocellular Carcinoma. Gastroenterology, 2020, 159, 434-436.	0.6	5
304	Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2. Cell Discovery, 2022, 8, 43.	3.1	5
305	Food-Induced Asthma in China: An Analysis in 40 Cases: Original Articles. Journal of Asthma, 1991, 28, 415-418.	0.9	4
306	Addition of Anti-neu Antibody to Local Irradiation Can Improve Tumor-Bearing BALB/c Mouse Survival through Immune-Mediated Mechanisms. Radiation Research, 2015, 183, 271.	0.7	4

#	Article	IF	Citations
307	The tragic fate of group 3 innate lymphoid cells during HIV-1 infection. Journal of Clinical Investigation, 2015, 125, 3430-3432.	3.9	4
308	Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts. SSRN Electronic Journal, 0, , .	0.4	4
309	Anti-HER2/Neu passive-aggressive immunotherapy. OncoImmunology, 2014, 3, e27296.	2.1	3
310	Response to Field. Journal of Clinical Investigation, 2006, 116, 3088-3089.	3.9	3
311	Deflating the Lymph Node. Immunity, 2011, 34, 8-10.	6.6	2
312	Degradation of CTLA-4 balances toxicity and efficacy. Science Bulletin, 2019, 64, 1388-1389.	4.3	2
313	Attenuation by Targeting the B- and T-Cell Attenuator. Transplantation, 2011, 92, 1075-1076.	0.5	1
314	Lymphotoxin beta receptor is required for the migration and selection of autoreactive T cells in thymic medulla. FASEB Journal, 2008, 22, 669.13.	0.2	1
315	Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine. Cell Research, 2022, 32, 331-332.	5.7	1
316	Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. Journal of Cell Biology, 2007, 176, i6-i6.	2.3	0
317	Hypersensitivity of innate response to TLRs in neonate. FASEB Journal, 2008, 22, 672.9.	0.2	0
318	The Prognostic Significance of Tumor-Infiltrating Lymphocytes. , 2010, , 385-407.		0
319	Abstract A112: Manipulating tumor microenvironment for immunotherapy. , 2016, , .		0
320	Abstract 4557: Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. , 2018, , .		0
321	Abstract 2752: EGFR tyrosine kinase inhibitor limits tumor relapse through enhancing anti-tumor T cell responses. , 2018, , .		0
322	Abstract PR13: Polymerase-mediated ultramutagenesis: A new approach for modeling the high mutational load of human cancer. , 2020, , .		0
323	Abstract 973: Telomere stress potentiates host STING-dependent anti-tumor immunity. , 2020, , .		0
324	Autoimmune Diseases. , 2006, , 97-115.		0

#	Article	IF	Citations
325	602â€…AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells. , 2021, 9, A632-A632.		0